Notice: This company has been marked as potentially delisted and may not be actively trading. Elicio Therapeutics (ELTX) News Today Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesOwnershipShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 Time Period Elicio Therapeutics Reports Inducement GrantsOctober 16, 2024 | globenewswire.comElicio Therapeutics Inc.: Elicio Therapeutics Reports Inducement GrantsSeptember 19, 2024 | finanznachrichten.deElicio Therapeutics Reports Inducement GrantsSeptember 17, 2024 | globenewswire.comElicio Therapeutics Announces Three Upcoming Presentations Focused on its Lymph Node Targeted, mKRAS-Specific Amphiphile VaccinesSeptember 13, 2024 | globenewswire.comElicio Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceAugust 28, 2024 | globenewswire.comElicio Therapeutics: A Strong Buy on Improved Financials and Promising Clinical TrialsAugust 23, 2024 | markets.businessinsider.comElicio Therapeutics Inc.: Elicio Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate UpdatesAugust 14, 2024 | finanznachrichten.deELTX Stock Earnings: Elicio Therapeutics Beats EPS for Q2 2024August 13, 2024 | markets.businessinsider.comElicio Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate UpdatesAugust 13, 2024 | globenewswire.comElicio Therapeutics Announces Closing of Private Placement of $20.0 Million Convertible NoteAugust 13, 2024 | finance.yahoo.comElicio Therapeutics, Inc. (ELTX)August 2, 2024 | finance.yahoo.comWhy Is Elicio Therapeutics (ELTX) Stock Down 36% Today?June 28, 2024 | investorplace.comElicio Therapeutics Announces Preliminary Disease-Free Survival analysis from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7PJune 27, 2024 | globenewswire.comElicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual MeetingMay 23, 2024 | globenewswire.comElicio Therapeutics: Strong Buy on Promising ELI-002 Vaccine Clinical Data and Market PotentialMay 22, 2024 | markets.businessinsider.comElicio Therapeutics, Inc.: Elicio Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdatesMay 16, 2024 | finanznachrichten.deELTX Stock Earnings: Elicio Therapeutics Beats EPS for Q1 2024May 16, 2024 | investorplace.comElicio Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdatesMay 15, 2024 | globenewswire.comElicio Therapeutics to Present New Preliminary Data from the Ongoing AMPLIFY-7P Phase 1/2 Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual MeetingApril 25, 2024 | globenewswire.comRobert Connelly Elicio Therapeutics, Inc.'s (NASDAQ:ELTX) CEO is the most bullish insider, and their stock value gained 11%last weekApril 13, 2024 | finance.yahoo.comElicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual MeetingApril 5, 2024 | globenewswire.comELTX Stock Earnings: Elicio Therapeutics Misses EPS for Q4 2023April 2, 2024 | investorplace.comElicio Therapeutics, Inc.: Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate UpdatesMarch 29, 2024 | finanznachrichten.deElicio Therapeutics Reports 2023 Financial Results and Provides Corporate UpdatesMarch 29, 2024 | globenewswire.comElicio Therapeutics Shares Rise 27% After Private PlacementMarch 19, 2024 | marketwatch.comElicio Therapeutics to sell 1.03M shares $5.81 in private placement financingMarch 18, 2024 | msn.comElicio Therapeutics Announces $6.0 Million Private Placement FinancingMarch 18, 2024 | globenewswire.comElicio Therapeutics Announces Upcoming Presentations at the American Association for Cancer Research (AACR) Annual MeetingMarch 6, 2024 | globenewswire.comElicio Therapeutics Stock (NASDAQ:ELTX), Short Interest ReportFebruary 23, 2024 | benzinga.comElicio Therapeutics Announces Publication Of Preclinical Data Demonstrating Power Of Amphiphile-ImmunotherapyFebruary 5, 2024 | benzinga.comElicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceFebruary 5, 2024 | finance.yahoo.comElicio Therapeutics Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid TumorsJanuary 25, 2024 | finance.yahoo.comElicio Therapeutics to Present ELI-002 7P (AMPLIFY-7P) Trial in Progress Poster on Phase 1/2 Study of Lymph Node-Targeted Vaccine at ASCO GI SymposiumJanuary 17, 2024 | finance.yahoo.comElicio Therapeutics to Present at the B. Riley Securities 4th Annual Oncology ConferenceJanuary 16, 2024 | finance.yahoo.comElicio Therapeutics Inc.: Elicio Therapeutics Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer StudyJanuary 11, 2024 | finanznachrichten.deNature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutic’s AMPLIFY-201 Phase 1 Solid Tumor Study of ELI-002January 9, 2024 | finance.yahoo.comTrading was temporarily halted for "ELTX" at 09:01 AM with a stated reason of "LULD pause."January 9, 2024 | marketbeat.comTrading was temporarily halted for "ELTX" at 10:01 AM with a stated reason of "LULD pause." Trading set to resume at 10:01 AM. January 3, 2024 | marketbeat.comTrading was temporarily halted for "ELTX" at 09:12 AM with a stated reason of "LULD pause."December 29, 2023 | marketbeat.comTrading was temporarily halted for "ELTX" at 09:12 AM with a stated reason of "LULD pause."December 27, 2023 | marketbeat.comElicio Therapeutics director buys stock worth $7MDecember 27, 2023 | msn.comElicio Therapeutics 10% owner purchases stake worth $7.05MDecember 26, 2023 | msn.comElicio Therapeutics to sell 1.2M shares at $5.81 in private placementDecember 22, 2023 | msn.comELTX Elicio Therapeutics, Inc.December 22, 2023 | seekingalpha.comElicio Therapeutics Announces $7.0 Million Private Placement FinancingDecember 22, 2023 | finance.yahoo.comA Look At Elicio Therapeutics’ (NASDAQ: ELTX) Pipeline: What Does This Cancer-Fighting Company Have In Store For The Future?December 15, 2023 | finance.yahoo.comA Look At Elicio Therapeutics' (NASDAQ: ELTX) Pipeline: What Does This Cancer-Fighting Company Have In Store For The Future?December 14, 2023 | benzinga.comElicio Therapeutics to Present at the H.C. Wainwright 4th Annual Precision Oncology Virtual ConferenceDecember 4, 2023 | finance.yahoo.comBuy Rating Upheld for Elicio Therapeutics Amid Solid Financial Position and Promising Clinical ResultsNovember 14, 2023 | markets.businessinsider.comElicio Therapeutics reports Q3 resultsNovember 10, 2023 | msn.com Get Elicio Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ELTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Billionaires Spot Once-In-25-Year Wealth Opportunity (Ad)Why November 7th Will Impact Stocks More Than The Election Just 48 hours after the 2024 Presidential Election… A man from a completely different government branch is going to stand up, say a few words… and make history in the stock market. Click here for the full story. ELTX Media Mentions By Week ELTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ELTX News Sentiment▼0.000.40▲Average Medical News Sentiment ELTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ELTX Articles This Week▼01▲ELTX Articles Average Week Get Elicio Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ELTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies NKTX News Today CRBP News Today RZLT News Today GLTO News Today OGI News Today DMAC News Today ATOS News Today VTYX News Today GLSI News Today FBRX News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ELTX) was last updated on 10/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredMusk warns humanity: “Obsolete”The 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonPorter & Company | Sponsored #1 Pre-IPO Opportunity For 2024 [Take Action Now!]According to James, the largest IPO in history could kick off in a matter of weeks. I’m talking about Starl...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredGoldman Sachs’ AI warningAfter warning of last year's historic bank run, weeks in advance... Legendary stock-picker Marc Chaikin jus...Chaikin Analytics | SponsoredAmerica’s Election NightmareThanks to a new law signed by President Biden, a small group of powerful people could decide who is installed ...Banyan Hill Publishing | SponsoredIt’s delivered 859% in 2.5 months…We’ve gotten a lot of messages asking… what should we buy if Trump wins? What should we buy if Kamala wins?...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Elicio Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Elicio Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ELTX Stock Alerts